Peak Bio, Inc. (PKBO)

OTCMKTS · Delayed Price · Currency is USD
0.0215
-0.0185 (-46.25%)
At close: Sep 17, 2024
-91.19%
Market Cap 497.19K
Revenue (ttm) 354.02K
Net Income (ttm) -4.63M
Shares Out 23.12M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Open 0.0215
Previous Close 0.0400
Day's Range 0.0215 - 0.0215
52-Week Range 0.0020 - 0.6880
Beta 0.22
Analysts n/a
Price Target n/a
Earnings Date Nov 22, 2024

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company’s lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate in preclinical trials for solid tumors. Peak Bio, Inc. is based in Pleasanton, California. [Read more]

Industry Biotechnology
Sector Healthcare
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol PKBO
Full Company Profile

Financial Performance

In 2023, Peak Bio's revenue was $367,877, a decrease of -39.46% compared to the previous year's $607,681. Losses were -$12.83 million, -2.01% less than in 2022.

Financial Statements

News

There is no news available yet.